Update on Cannabidiol in Drug-Resistant Epilepsy

Area of Science:

• Neurology
• Pharmacology
• Pediatrics

Background:

• Drug-resistant epilepsy (DRE) presents significant challenges in pediatric populations.
• Cannabidiol (CBD) is emerging as a potential therapeutic agent for specific pediatric epilepsy syndromes.
• Regulatory approvals for CBD in DRE exist in the US, Europe, and India.

Purpose of the Study:

• To review the pharmacological properties and mechanisms of action of CBD.
• To evaluate clinical evidence for CBD in pediatric epilepsies like Lennox Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC).
• To examine the regulatory status and cost-effectiveness of CBD in India.

Main Methods:

• Review of clinical trials and observational studies on CBD efficacy and safety.
• Analysis of pharmacological data and proposed mechanisms of action.
• Assessment of the regulatory landscape and economic factors in India.

Main Results:

• CBD demonstrates potential in reducing seizure frequency and enhancing quality of life for children with DRE.
• Common adverse events are generally mild, including somnolence and gastrointestinal issues.
• The cost of CBD poses a significant barrier to access, particularly in low- and middle-income countries.

Conclusions:

• CBD is a promising treatment for pediatric DRE, with established efficacy and a generally favorable safety profile.
• Further research and policy development are needed to address cost and accessibility challenges, especially in India.
• Integrating CBD into clinical practice requires careful consideration of its pharmacological, clinical, and economic aspects.